

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.

Date: 13.02.2021

Dear Sir/Madam,

Sub: Outcome of board meeting under regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: Sangam Health Care Products Limited (Scrip code: 531625)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Sangam Health Care Products Limited held on Saturday, the 13th day of February, 2021 at 04:00 P.M. at the registered office of the company were duly considered and approved by the Board:

1. Un-audited Financial Results of the company as per IndAS for the quarter ended December 31, 2020 and
2. Limited review report of auditors thereon.

The meeting of the Board of Directors commenced at 04.00 P.M (IST) and concluded at 5.00 P.M (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,

For Sangam Health Care Products Limited



A. Bala Gopal
Managing Director
DIN: (01712903)

Encl: as above

SANGAM HEALTH CARE PRODUCTS LIMITED

CIN:L24230TG1993PLC016731

Statement of Un-Audited Results for the Quarter Ended and Nine Months Ended 31.12.2020

(Amount Rs.in Lakhs)

S.No.	Particulars	For the Quarter ended			Nine Months Ended		Year Ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
I.	Revenue from Operations	225.92	315.45	609.10	848.30	1,784.73	2,180.55
II.	Other Income	-	-	-	-	315.31	1.78
III.	Total income (I+II)	225.92	315.45	609.10	848.30	2,100.04	2,182.33
IV.	Expenses						
	(a) Cost of Materials consumed	84.49	97.40	312.17	317.72	850.73	1,024.09
	(b) Purchase of stock-in-trade	-	-	-	-	-	(39.29)
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4.32)	89.41	(23.06)	155.35	42.91	
	(d) Employee benefits expense	329.83	60.96	233.47	436.81	485.68	552.44
	(e) Finance Cost	0.53	0.07	25.49	0.65	131.98	29.45
	(f) Depreciation and amortisation expense	31.39	31.38	42.53	94.16	114.21	125.54
	(h) Other expenses	65.68	64.04	56.13	199.25	238.71	440.05
	Total Expenses	507.61	343.26	646.73	1,203.95	1,864.22	2,132.28
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	(281.69)	(27.81)	(37.63)	(355.65)	235.82	50.05
VI.	Exceptional Items	-	-	-	-	-	(291.54)
VII.	Profit / (Loss) from before tax (V-VI)	(281.69)	(27.81)	(37.63)	(355.65)	235.82	341.59
VIII.	Tax expense						
	Current Tax	-	-	-	-	-	(63.94)
	Deferred Tax	-	-	-	-	-	-
IX.	Net Profit / (Loss) for the period from Continuing operations (VII-VIII)	(281.69)	(27.81)	(37.63)	(355.65)	235.82	405.53
X.	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI.	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII.	Profit/ (Loss) from discontinuing operations after tax	-	-	-	-	-	-
XIII.	Profit/(loss) for the Period (IX+XII)	(281.69)	(27.81)	(37.63)	(355.65)	235.82	405.53
XIV.	Other Comprehensive Incomes						
A).	(i) Items that will not be recycled to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B).	(i) Items that may be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive Income	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII+XIV)	(281.69)	(27.81)	(37.63)	(355.65)	235.82	405.53
XVI.	Earnings Per Equity Share of face value of Rs.10/- each (for Continuing operations):						
	1) Basic	(1.90)	(0.19)	(0.25)	(2.39)	1.59	2.73
	2) Diluted	(1.90)	(0.19)	(0.25)	(2.39)	1.59	2.73
XVII.	Earnings Per Equity Share of face value of Rs.10/- each (for Discontinuing operations):						
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XVIII.	Earnings Per Equity Share of face value of Rs.10/- each (for Continued and Discontinuing operations):						
	1) Basic	(1.90)	(0.19)	(0.25)	(2.39)	1.59	2.73
	2) Diluted	(1.90)	(0.19)	(0.25)	(2.39)	1.59	2.73
XIX.	Paid-up equity share capital (Face Value of Rs. 10/- per share)	1,486.07	1,486.07	1,486.07	1,486.07	1,486.07	1,486.07


NOTES:

- The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 13/02/2021.
- These results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
- The Company is engaged in manufacturing and sale of medical products hence there are no separate reportable segments as per Ind AS - 108 "Operating Segments".

For SANGAM HEALTHCARE PRODUCTS LIMITED

A. Balagopal
A. Balagopal
Chairman and Managing Director
DIN:01712903

Place : Hyderabad
Date : 13/02/2021



M M REDDY & CO.,

Chartered Accountant

LIMITED REVIEW REPORT

Phone : 040-65536097

Fax : 040-23478836

Mobile : 98482 71555

91770 20555

Review report to
The Board of Directors,
SANGAM HEALTH CARE PRODUCTS LIMITED

We have reviewed the accompanying statement of Un-audited Financial Results of **SANGAM HEALTH CARE PRODUCTS LIMITED** or the quarter ended **31st December, 2020** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M M REDDY & CO.,
Chartered Accountants

Firm Reg No. 0103716

M Madhusudhana Reddy
Partner

Membership No. 213077

UDIN: 21213077AAAADD6377



Place: Hyderabad
Date: 13/02/2021

